List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11668030/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clinical Infectious Diseases, 2023, 76, e533-e536.	2.9	7
2	Long-term Memory Response After a Single Intramuscular Rabies Booster Vaccination 10–24 Years After Primary Immunization. Journal of Infectious Diseases, 2022, 226, 1052-1056.	1.9	6
3	Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019. Clinical Infectious Diseases, 2022, 75, 1046-1053.	2.9	4
4	A review of severe thrombocytopenia in Zika patients – Pathophysiology, treatment and outcome. Travel Medicine and Infectious Disease, 2022, 45, 102231.	1.5	2
5	Immunogenicity of a 5â€dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2022, 97, 592-602.	2.0	9
6	Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy. Vaccines, 2022, 10, 795.	2.1	6
7	Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy. International Journal of Antimicrobial Agents, 2022, 60, 106629.	1.1	4
8	Searching and Finding the Hidden Treasure: A Retrospective Analysis of Rickettsial Disease Among Dutch International Travelers. Clinical Infectious Diseases, 2021, 72, 1171-1178.	2.9	6
9	Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. Lancet Infectious Diseases, The, 2021, 21, 711-721.	4.6	21
10	Travel-related infections presenting in Europe: A 20-year analysis of EuroTravNet surveillance data. Lancet Regional Health - Europe, The, 2021, 1, 100001.	3.0	27
11	Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study. International Journal of Infectious Diseases, 2021, 106, 237-245.	1.5	8
12	Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: A systematic review. Travel Medicine and Infectious Disease, 2021, 41, 102007.	1.5	13
13	Destination shapes antibiotic resistance gene acquisitions, abundance increases, and diversity changes in Dutch travelers. Genome Medicine, 2021, 13, 79.	3.6	20
14	SARS-CoV-2 vaccination for patients with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 523.	3.7	1
15	Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine. Travel Medicine and Infectious Disease, 2021, 43, 102093.	1.5	4
16	European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical Microbiology and Infection, 2021, 27, S1-S21.	2.8	242
17	Human Transmission of <i>Blastocystis</i> by Fecal Microbiota Transplantation Without Development of Gastrointestinal Symptoms in Recipients. Clinical Infectious Diseases, 2020, 71, 2630-2636.	2.9	25
18	Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus–Infected Individuals in a High-income Setting. Clinical Infectious Diseases, 2020, 71, 41-50.	2.9	28

#	Article	IF	CITATIONS
19	Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in a population of Dutch travellers: A cross-sectional study. Travel Medicine and Infectious Disease, 2020, 33, 101547.	1.5	16
20	Faecal microbiota transplantation for <i>Clostridioides difficile</i> infection: Four years' experience of the Netherlands Donor Feces Bank. United European Gastroenterology Journal, 2020, 8, 1236-1247.	1.6	35
21	Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 2020, 37, 101868.	1.5	57
22	Added value of chest computed tomography in suspected COVID-19: an analysis of 239 patients. European Respiratory Journal, 2020, 56, 2001377.	3.1	22
23	Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100576.	3.2	17
24	COVID-19 treatment in sub-Saharan Africa: If the best is not available, the available becomes the best. Travel Medicine and Infectious Disease, 2020, 37, 101878.	1.5	9
25	Antibody response in Dutch marines to a single intramuscular rabies booster immunization 1–2.5 years after an intradermal pre-exposure schedule: An observational study. Travel Medicine and Infectious Disease, 2020, 38, 101907.	1.5	1
26	Can dengue virus be sexually transmitted?. Travel Medicine and Infectious Disease, 2020, 38, 101753.	1.5	1
27	Epidemiology of rabies cases among international travellers, 2013–2019: A retrospective analysis of published reports. Travel Medicine and Infectious Disease, 2020, 36, 101766.	1.5	19
28	Carriage of Blastocystis spp. in travellers - A prospective longitudinal study. Travel Medicine and Infectious Disease, 2019, 27, 87-91.	1.5	18
29	Reply to Zhao and Miao and to Chen et al." Is the rabies virus neutralizing antibody titerstable during long-term storage?. Travel Medicine and Infectious Disease, 2019, 32, 101502.	1.5	1
30	Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 2019, 32, 101479.	1.5	18
31	Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease. Clinical Infectious Diseases, 2019, 70, 595-604.	2.9	20
32	Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine, 2019, 37, 510-515.	1.7	12
33	Risk of acquisition of human diarrhoeagenic Escherichia coli virulence genes in intercontinental travellers: A prospective, multi-centre study. Travel Medicine and Infectious Disease, 2019, 31, 101362.	1.5	9
34	A Modified Case Definition to Facilitate Essential Hospital Care During Ebola Outbreaks. Clinical Infectious Diseases, 2019, 68, 1763-1768.	2.9	6
35	No detection of Zika virus infection in asymptomatic Dutch military personnel after deployment in high endemic areas (Belize, Curacao, Saint Martin) from December 2016 to December 2017. Travel Medicine and Infectious Disease, 2019, 27, 119-120.	1.5	2
36	Under-diagnosis of rickettsial disease in clinical practice: A systematic review. Travel Medicine and Infectious Disease, 2018, 26, 7-15.	1.5	23

#	Article	IF	CITATIONS
37	Rabies antibody response after two intradermal pre-exposure prophylaxis immunizations: An observational cohort study. Travel Medicine and Infectious Disease, 2018, 22, 36-39.	1.5	15
38	Travel-related health problems in the immunocompromised traveller: An exploratory study. Travel Medicine and Infectious Disease, 2018, 25, 50-57.	1.5	10
39	Updated Zika virus recommendations are needed. Lancet, The, 2018, 392, 818-819.	6.3	8
40	The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine, 2018, 36, 5832-5845.	1.7	57
41	Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis. Travel Medicine and Infectious Disease, 2018, 24, 89-100.	1.5	82
42	Travel-related leptospirosis in the Netherlands 2009–2016: An epidemiological report and case series. Travel Medicine and Infectious Disease, 2018, 24, 44-50.	1.5	9
43	Ebola 2018 – Implications for travel health advice and relevance for travel medicine. Travel Medicine and Infectious Disease, 2018, 24, 1-3.	1.5	3
44	Leptospirosis among Returned Travelers: A GeoSentinel Site Survey and Multicenter Analysis—1997–2016. American Journal of Tropical Medicine and Hygiene, 2018, 99, 127-135.	0.6	12
45	Yellow fever vaccination – Once in a lifetime?. Travel Medicine and Infectious Disease, 2017, 15, 1-2.	1.5	19
46	Long-term sequelae of chikungunya virus disease: A systematic review. Travel Medicine and Infectious Disease, 2017, 15, 8-22.	1.5	136
47	Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Therapeutic Advances in Gastroenterology, 2017, 10, 373-381.	1.4	35
48	Neuropsychological long-term sequelae of Ebola virus disease survivors – A systematic review. Travel Medicine and Infectious Disease, 2017, 18, 18-23.	1.5	49
49	Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus–Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus–Uninfected Controls. Journal of Infectious Diseases, 2017, 216, 622-631.	1.9	51
50	Clostridium difficile infection in returning travellers. Journal of Travel Medicine, 2017, 24, .	1.4	27
51	Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine. Lancet, The, 2017, 389, 578-580.	6.3	3
52	Travel-Associated Zika Virus Disease Acquired in the Americas Through February 2016. Annals of Internal Medicine, 2017, 166, 99.	2.0	67
53	Travel-related acquisition of diarrhoeagenic bacteria, enteral viruses and parasites in a prospective cohort of 98 Dutch travellers. Travel Medicine and Infectious Disease, 2017, 19, 33-36.	1.5	16
54	Pre-travel care for immunocompromised and chronically ill travellers: A retrospective study. Travel Medicine and Infectious Disease, 2017, 19, 37-48.	1.5	8

#	Article	IF	CITATIONS
55	Global phylogenetic analysis of Escherichia coli and plasmids carrying the mcr-1 gene indicates bacterial diversity but plasmid restriction. Scientific Reports, 2017, 7, 15364.	1.6	230
56	Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infectious Diseases, The, 2017, 17, 78-85.	4.6	340
57	Complications, effectiveness, and long term followâ€up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent <i>Clostridium difficile</i> infection. United European Gastroenterology Journal, 2017, 5, 868-879.	1.6	64
58	Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Eurosurveillance, 2016, 21, .	3.9	151
59	Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers. Future Microbiology, 2016, 11, 857-864.	1.0	50
60	Zika virus infection in 18 travellers returning from Surinam and the Dominican Republic, The Netherlands, November 2015–March 2016. Infection, 2016, 44, 797-802.	2.3	35
61	Uncommon presentation of Zika fever or co-infection? – Authors' reply. Lancet, The, 2016, 387, 1813-1814.	6.3	4
62	Zika virus: who's next?. Lancet Infectious Diseases, The, 2016, 16, 1204-1205.	4.6	3
63	Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication. Vaccine, 2016, 34, 1247-1251.	1.7	21
64	Zika virus and the risk of imported infection in returned travelers: Implications for clinical care. Travel Medicine and Infectious Disease, 2016, 14, 13-15.	1.5	42
65	Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection. Lancet, The, 2016, 387, 939-940.	6.3	82
66	A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS ONE, 2016, 11, e0149871.	1.1	80
67	Response to Hepatitis A Vaccination in Immunocompromised Travelers. Journal of Infectious Diseases, 2015, 212, 378-385.	1.9	46
68	<i>Editorial Commentary: Clostridium difficile</i> Ribotype 027: An Intrinsically Virulent Strain, but Clinical Virulence Remains to Be Determined at the Bedside. Clinical Infectious Diseases, 2015, 61, 242-243.	2.9	3
69	Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infectious Diseases, The, 2015, 15, 55-64.	4.6	206
70	The Carriage Of Multiresistant Bacteria After Travel (COMBAT) prospective cohort study: methodology and design. BMC Public Health, 2014, 14, 410.	1.2	35
71	Diagnosis and subtype analysis of Blastocystis sp.in 442 patients in a hospital setting in the Netherlands. BMC Infectious Diseases, 2013, 13, 389.	1.3	86
72	All-Cause and Disease-Specific Mortality in Hospitalized Patients With Clostridium difficile Infection: A Multicenter Cohort Study. Clinical Infectious Diseases, 2013, 56, 1108-1116.	2.9	113

#	Article	IF	CITATIONS
73	Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. Journal of Antimicrobial Chemotherapy, 2012, 67, 742-748.	1.3	306
74	Health Risks of Travelers With Medical Conditions—A Retrospective Analysis. Journal of Travel Medicine, 2012, 19, 104-110.	1.4	58
75	<i>Clostridium difficile</i> PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environmental Microbiology, 2009, 11, 505-511.	1.8	154
76	Emergence of <i>Clostridium difficile</i> Infection Due to a New Hypervirulent Strain, Polymerase Chain Reaction Ribotype 078. Clinical Infectious Diseases, 2008, 47, 1162-1170.	2.9	577
77	Clostridium difficile PCR Ribotype 078: an Emerging Strain in Humans and in Pigs?. Journal of Clinical Microbiology, 2008, 46, 1157-1158.	1.8	113
78	Novel Risk Factors for <i>Clostridium difficile</i> –Associated Disease in a Setting of Endemicity?. Clinical Infectious Diseases, 2008, 47, 429-430.	2.9	9